Nicole van der Weerden
Follow
Get notifications in MyBN when activity occurs.
Nicole van der Weerden
Chief Operating Officer / Arovella Therapeutics
Most Notable Role
Dr Nicole van der Weerden has over 15 years of leadership experience in the biotechnology industry, driving business objectives including pre-clinical discovery, proof-of-concept, manufacturing, and clinical
development.
Prior to becoming the chief operating officer of Arovella Therapeutics in January 2023, Dr van der Weerden was the chief operating officer and executive director of ASX-listed biotechnology company Hexima where she led the strategic pivot of the company from an agricultural biotechnology company to a human therapeutics company. She also led the financing and development strategy, pre-clinical and clinical programs, manufacturing and worldwide patent strategy for Hexima’s lead asset, pezadeftide.
Dr van der Weerden holds a PhD in Biochemistry from La Trobe University. Her PhD research on the antifungal properties and mechanism of action of plant defensins led to the award of a prestigious Victoria Fellowship in 2006. She also holds an MBA from Melbourne Business School, and is a graduate of the Australian Institute of Company Directors.
development.
Prior to becoming the chief operating officer of Arovella Therapeutics in January 2023, Dr van der Weerden was the chief operating officer and executive director of ASX-listed biotechnology company Hexima where she led the strategic pivot of the company from an agricultural biotechnology company to a human therapeutics company. She also led the financing and development strategy, pre-clinical and clinical programs, manufacturing and worldwide patent strategy for Hexima’s lead asset, pezadeftide.
Dr van der Weerden holds a PhD in Biochemistry from La Trobe University. Her PhD research on the antifungal properties and mechanism of action of plant defensins led to the award of a prestigious Victoria Fellowship in 2006. She also holds an MBA from Melbourne Business School, and is a graduate of the Australian Institute of Company Directors.
Lists and Charts
Total Shareholder Return as at 28/06/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| th | LawFinance | 0% | -77% |
| 49th | Arovella Therapeutics | 180% | 116% |
1769 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 974th |  | Arovella Therapeutics | $1.5m |
| 1300th | | LawFinance | -$24.9m |
| 1303rd |  | Ellerston Asian Investment | -$35.8m |
| 1306th | | VGI Partners Asian Investments | -$107.4m |
1330 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| NEW ROLE: Non-Executive Director, Hexima | 04 Jan 2023 |
| NEW ROLE: Chief Operating Officer, Arovella Therapeutics | 04 Jan 2023 |
| NEW ROLE: Chief Operating Officer, Executive Director, Hexima | 07 Apr 2022 |
